PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 11, 2026

A BcfA-containing intranasal vaccine generated TH17 immunity and reduced B. bronchiseptica colonization and disease in mice.

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlexa R AubreyKPKomal PatelJHJesse M. Hall

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates reduced B. bronchiseptica colonization and disease in mice, suggesting effective immunization for broader use.

Key Points

  • To investigate the efficacy of a BcfA-containing intranasal vaccine in generating TH17 immunity against B. bronchiseptica in mice.
  • Immunized mice were challenged with B. bronchiseptica to assess protection from infection.
  • Measured systemic and mucosal IgG and IgA antibodies and characterized T cell responses.
  • Evaluated weight loss, bronchoconstriction, cough, and lung inflammation in immunized versus control mice.
  • Immunized mice showed significant protection against weight loss and reduced bronchoconstriction (p<0.01).
  • Lung inflammation decreased significantly in vaccinated mice compared to controls (p<0.05).
  • B. bronchiseptica was cleared from the lungs of immunized mice and significantly reduced in the nasal cavity.

Cite This Study

Aubrey et al. (2026) studied this question.

synapsesocial.com/papers/6a0171ed3a9f334c28271f31https://doi.org/10.1038/s41541-026-01472-2
View Full Paper
Ask AI
Bookmark
Share